(Reuters) – Teva Pharmaceutical Industries Ltd. has reached a $ 225 million deal to resolve allegations that the drugmaker incited an opioid epidemic in Texas by improperly marketing addictive painkillers, state prosecutors said on Monday.
Texas Attorney General. General Ken Paxton said Teva agreed to pay $ 150 million over 15 years and provide generic Narcan worth $ 75 million, a drug used to counteract the effects of opioid overdoses.
The deal is the largest Teva has met in the more than 3,500 lawsuits. it faces attempts to hold it and other drug companies responsible for an opioid abuse epidemic that has led to hundreds of thousands of overdose deaths over the past two decades nationally.
The Israeli drugmaker previously settled with Oklahoma and Louisiana. Teva did not recognize crime as part of Monday's deal.
Teva has long sought to address the thousands of state, county and municipal opioid lawsuits it faces, offering in 2019 to donate $ 23 billion in opioid addiction drugs and pay 250 $ 196 million over 10 years.
Attorneys general from four states, including Texas, negotiated that proposal with Teva. But no nationwide conciliation agreement ultimately resulted after lawyers for some of the plaintiffs questioned the true value of the drugs.
Kåre Schultz, Teva's CEO, said in a statement that it "continues in Teva's best interest to put these cases behind us. and continue to focus on the patients we serve every day. "
The settlement came after a jury in a similar case in the state of New York and two counties in December found Teva responsible for allegations that they engaged in misleading marketing practices that incited
A California judge a month earlier ruled that Teva and three other drugmakers could not be held responsible for causing the epidemic in several major counties in that state.